Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

The Radiation Syndrome Treatment Market will register a CAGR of more than 6% by 2023

Reportlinker
Posted on: 04 Dec 18
The Radiation Syndrome Treatment Market will register a CAGR of more than 6% by 2023

PR Newswire

NEW YORK, Dec. 4, 2018

NEW YORK, Dec. 4, 2018 /PRNewswire/ -- 109 pages, November 2018

About this market
The advent of regenerative therapy is expected to help the market grow. The global radiation syndrome treatment market has seen strong advances in terms of treatment options. The advent of regenerative medicines such as stem-cell therapy is one among such advances. In stem-cell therapy, the stem cells are taken from the patient and are re-inserted to replace the damaged cells to treat or prevent a disease. Technavio's analysts have predicted that the radiation syndrome treatment market will register a CAGR of more than 6% by 2023.

Read the full report: https://www.reportlinker.com/p05638943

Market Overview
Increase in nuclear testing
The increasing nuclear testing in South-East Asia in recent years has resulted in the rise in the symptoms of radiation toxicity and exposure in nearby countries. also, various scientists and pharmaceutical companies believe that the increasing testing of nuclear launches cause significant damage to the environment.
Difficult to diagnose
A major share of the global radiation syndrome treatment market is dominated by acute radiation syndrome, which is highly progressive by nature. Acute radiation effects the patients in less than 24 hours of exposure to radiation. The lack of diagnostic devices for radiation syndrome is major challenge faced by the market.
For the detailed list of factors that will drive and challenge the growth of the radiation syndrome treatment market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Amgen and Neumedicines the competitive environment is quite intense. Factors such as the increase in nuclear testing and the advent of regenerative therapy, will provide considerable growth opportunities to radiation syndrome treatment manufactures. Amgen, Neumedicines, Partner Therapeutics, Tonix Pharmaceuticals, and Onconova Therapeutics are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. The market is expected to witness the emergence of many international and regional radiation syndrome therapeutic companies who offer therapeutics for the treatment of HSC syndrome, CNS syndrome, GI syndrome, and cardiovascular syndrome caused by radiation poisoning.'

Read the full report: https://www.reportlinker.com/p05638943

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-radiation-syndrome-treatment-market-will-register-a-cagr-of-more-than-6-by-2023-300760051.html

SOURCE Reportlinker

PR Newswire
www.prnewswire.com

Last updated on: 04/12/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.